Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
|Journal||Journal of Medical Virology|
|Date||July 9, 2020|
Retrospective analysis of patients with systemic lupus erythematosus, rheumatoid arthritis and other autoimmune disorders showed that patients receiving hydroxychloroquine had an odds ratio of COVID-19 of 0.51 (CI 0.37-0.70) compared to patients with autoimmune diseases who were receiving other therapeutics.
This analysis suggests a prophylactic effect of hydroxychloroquine against COVID-19.
Of note, hydroxychloroquine was not shown to be entirely protective against COVID-19 as 5.96% of patients receiving chronic treatment with hydroxychloroquine still became infected with novel-coronavirus compared to the 7.45% infection incidence in patients not receiving hydroxychloroquine.
No major issues identified at this time.
No minor issues identified at this time.
This is another retrospective analysis that suggests a prophylactic effect of hydroxychloroquine against COVID-19.
None at this time.